BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26915300)

  • 1. Mutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease.
    Kamionek M; Ahmadi Moghaddam P; Sakhdari A; Kovach AE; Welch M; Meng X; Dresser K; Tomaszewicz K; Cosar EF; Mark EJ; Fraire AE; Hutchinson L
    Histopathology; 2016 Sep; 69(3):499-509. PubMed ID: 26915300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of BRAF
    Pierry C; Caumont C; Blanchard E; Brochet C; Dournes G; Gros A; Bandres T; Verdon S; Marty M; Bégueret H; Merlio JP
    Virchows Arch; 2018 Feb; 472(2):247-258. PubMed ID: 28711990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases.
    Roden AC; Hu X; Kip S; Parrilla Castellar ER; Rumilla KM; Vrana JA; Vassallo R; Ryu JH; Yi ES
    Am J Surg Pathol; 2014 Apr; 38(4):548-51. PubMed ID: 24625419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
    Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
    Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis.
    Dimmler A; Geddert H; Werner M; Faller G
    Virchows Arch; 2017 Apr; 470(4):429-435. PubMed ID: 28220299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.
    Pina-Oviedo S; Medeiros LJ; Li S; Khoury JD; Patel KP; Alayed K; Cason RC; Bowman CJ; Yin CC
    Mod Pathol; 2017 May; 30(5):734-744. PubMed ID: 28084334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH.
    McGinnis LM; Nybakken G; Ma L; Arber DA
    Am J Surg Pathol; 2018 Jul; 42(7):885-890. PubMed ID: 29649018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Childhood pulmonary Langerhans cell histiocytosis: a comprehensive clinical-histopathological and BRAF
    Kambouchner M; Emile JF; Copin MC; Coulomb-Lherminé A; Sabourin JC; Della Valle V; Sileo C; Ducou Le Pointe H; Bégueret H; Galmiche L; Lambilliotte A; Paraf F; Piche M; Piguet C; Rullier A; Secq V; Serre I; Bernaudin JF; Donadieu J
    Hum Pathol; 2019 Jul; 89():51-61. PubMed ID: 31054893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
    Tran G; Huynh TN; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.
    Mourah S; How-Kit A; Meignin V; Gossot D; Lorillon G; Bugnet E; Mauger F; Lebbe C; Chevret S; Tost J; Tazi A
    Eur Respir J; 2016 Jun; 47(6):1785-96. PubMed ID: 27076591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
    Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis.
    Chilosi M; Facchetti F; Caliò A; Zamò A; Brunelli M; Martignoni G; Rossi A; Montagna L; Piccoli P; Dubini A; Tironi A; Tomassetti S; Poletti V; Doglioni C
    Leuk Lymphoma; 2014 Nov; 55(11):2620-6. PubMed ID: 24471909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
    Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
    Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.
    Jouenne F; Chevret S; Bugnet E; Clappier E; Lorillon G; Meignin V; Sadoux A; Cohen S; Haziot A; How-Kit A; Kannengiesser C; Lebbé C; Gossot D; Mourah S; Tazi A
    Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31806714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
    Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
    Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
    Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
    Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
    Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
    Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations.
    Yousem SA; Dacic S; Nikiforov YE; Nikiforova M
    Chest; 2013 Jun; 143(6):1679-1684. PubMed ID: 23287985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis.
    Tóth B; Kiss N; Hársing J; Kárpáti S; Csomor J; Bödör C; Tímár J; Rásó E
    Virchows Arch; 2020 Nov; 477(5):749-753. PubMed ID: 32372223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
    Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
    Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.